The FDA has banned the use of a synthetic red dye used in oral medicines, as well as foods and dietary supplements, more than ...

In Part 3 of our Life Sciences Industry Report 2025, we share content from the last twelve months that delved into the ...

When healthcare brands leverage data to genuinely understand and connect with HCPs as unique individuals, the result is a ...

Looking ahead to 2025, small biopharma will continue its deliberate and ROI-driven approach to technology adoption. At the ...

Generative artificial intelligence (genAI) player Bioptimus has swelled its coffers with another financing round, raising $41 ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

For our final liveblog day we’re back at the Informa Biotech Showcase for more packed panels on AI and funding, a panel on ...

Continued pricing pressures from governments and patient groups are driving small molecule CDMOs to focus on reducing the ...

That is the conclusion of a report by the global Commission on Clinical Obesity – published in The Lancet Diabetes and ...